Drugmakers, health groups bring poor girls vaccine

May 9, 2013 by Linda A. Johnson
In this Friday, Feb. 2, 2007 file photo, one dose of the vaccine Gardasil, developed by Merck & Co., is displayed in Austin, Texas. On Thursday, May 9, 2013, the GAVI Alliance, a public-private partnership that's worked with drugmakers to deliver affordable vaccines to poor countries to treat childhood illnesses, announced a program that will team multinational drugmakers Merck & Co. and GlaxoSmithKline with top global health groups to protect millions of girls in the world's poorest countries from deadly cervical cancer. Merck & Co. and GlaxoSmithKline PLC initially will provide 2.4 million doses of their vaccines against cancer-causing human papilloma virus, for a fraction of the cost commanded in Western countries. Merck will supply its Gardasil for $4.50 per dose, and Glaxo its Cervarix for $4.60 per dose. In the U.S., the shots cost well over $100 apiece, and a three-dose series over six months is required.(AP Photo/Harry Cabluck, File)

Two multinational drugmakers are teaming up with top global health groups to protect millions of girls in the world's poorest countries from deadly cervical cancer.

Starting with pilot programs in eight Asian and African nations, the ambitious project ultimately is intended to inoculate more than 30 million in more than 40 countries by 2020. Given that most women killed by live in , the project could have a huge impact.

The endeavor was announced Thursday by the GAVI Alliance, a public-private partnership that's worked with drugmakers to deliver affordable vaccines to poor countries to treat that are big killers.

"This is a transformational moment for the health of women and girls across the world," said Dr. Seth Berkley, CEO of GAVI, which is short for Global Alliance for Vaccines and Immunization.

"A vast gap currently exists between girls in rich and poor countries. With GAVI's programs we can begin to bridge that gap so that all girls can be protected against cervical cancer no matter where they are born," he said in a statement.

Drugmakers & Co. and GlaxoSmithKline PLC initially will provide 2.4 million doses of their vaccines against cancer-causing human papilloma virus—for a fraction of the cost commanded in Western countries.

Merck will supply its Gardasil for $4.50 per dose, and Glaxo its Cervarix for $4.60 per dose. In the U.S., the shots cost well over $100 apiece, and a three-dose series over six months is required.

The vaccines protect against the strains of human papilloma virus, or HPV, that most commonly cause cancer. The virus, transmitted during sex, causes cervical cancer as well as vaginal, vulvar, anal and oral cancers. The vaccines prevent roughly 70 percent of those cancers.

In developed countries, older girls and women routinely get Pap tests to check for cervical cancer or signs of precancerous changes in cervical tissue. They're treated promptly, often before cancer begins, and few die. And increasingly, young girls and now boys as well are vaccinated with either Gardisil or Cervarix, starting as young as age 9 so they're protected well before they become sexually active.

Not so in poor countries.

"They don't have the benefit of screening to catch cancer early, when it can still be treated," Dr. Julie L. Gerberding, president of Merck Vaccines, said in an interview.

As a result, 85 percent of the 275,000 women killed by cervical cancer each year live in poor countries, where HPV is most prevalent.

"It is a disease that has devastating, life-threatening consequences and it is preventable," said Gerberding, an infectious diseases expert who's a former director of the Centers for Disease Control and Prevention. "Our aim is to do what we can to make the available."

The GAVI project will begin "demonstration projects" administering the vaccines to girls aged 9 to 13, starting in Kenya as early as this month. Then it will be expanded to Ghana, Laos, Madagascar, Malawi, Niger, Sierra Leone and Tanzania.

The goal is for the governments of those countries to show they can set up a national system—with medical staff, clinic supplies, distribution systems and supply management all well organized—to provide the vaccines over the long term. The program also will bring an opportunity to teach the girls about nutrition, sexual health and HIV prevention.

Already, GAVI is planning to provide the shots nationwide in Rwanda, starting next year.

Merck, based in Whitehouse Station, N.J., is providing 93 percent of the shots initially. It's also agreed to provide more shots at an even-lower price in the future, if higher volumes of vaccines are ordered, as that would reduce production costs.

Merck and Britain's GlaxoSmithKline are among the world's biggest makers of vaccines, and both have long provided many for free or at discounted prices to health programs in poor countries.

GAVI also will work with the heavy hitters of and development groups, including the CDC, the World Health Organization, UNICEF, the Bill & Melinda Gates Foundation and the World Bank. Other partners include the charities, corporations and 18 wealthy countries that help fund GAVi.

In the U.S., the vaccines have become steady money makers since they were launched a half-dozen years ago, but they haven't turned into the mega-sellers initially envisioned.

That's partly because of their high price here, but also because of political fights. Some conservative groups opposed the vaccines, arguing that giving adolescents a vaccine to protect them against a virus transmitted by sexual activity would encourage it.

Explore further: Partnership sees cervical vaccines for poorer countries

Related Stories

Partnership sees cervical vaccines for poorer countries

November 17, 2011
A major campaigner in vaccines for poorer countries announced plans on Thursday for innoculating up to two million women and girls against cervical cancer by 2015.

How cervical cancer vaccines came to be

January 19, 2013
(HealthDay)—The cervical cancer vaccine has turned into one of the biggest success stories in the field.

Study compares effectiveness of 2 vs. 3 doses of HPV vaccine for girls and young women

April 30, 2013
With the number of doses and cost of human papillomavirus (HPV) vaccines a barrier to global implementation, researchers have found that girls who received two doses of HPV vaccine had immune responses to HPV-16 and HPV-18 ...

Vaccines ready for 50 million in Africa's 'Meningitis Belt'

October 4, 2012
A huge vaccination campaign to protect 50 million people against meningitis has been launched in seven African countries aiming to stamp out the deadly virus, health officials said Thursday.

New studies shed light on what it cost to vaccinate girls against HPV in low income countries

November 12, 2012
Two studies published in BioMed Central's open access journal BMC Medicine examined the cost of delivering the human papillomavirus (HPV) vaccine to primary school girls in Tanzania. Both studies found that the cost of HPV ...

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.